Avadel announced that Kevin Springman has joined the company as Vice President of Sales. Avadel is executing a comprehensive commercial strategy to increase demand for LUMRYZ, with the goal of enhancing the experience for both patients and providers and unlocking the billion-dollar market potential of LUMRYZ. Avadel’s commercial launch in narcolepsy and ongoing progress in its investigational, Phase 3 trial in idiopathic hypersomnia positions the company to solidify its leadership in the sleep space and transform care for patients with sleep disorders.Most recently, Mr. Springman was an independent consultant to rare disease and specialty pharma companies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- IBM initiated, Southwest upgraded: Wall Street’s top analyst calls
- Avadel Pharmaceuticals initiated with a Buy at Deutsche Bank
- Avadel names Sev Melkonian as VP, patient services, distribution, reimbursement
- Avadel Pharmaceuticals price target lowered to $14 from $22 at UBS
- UBS cuts Avadel target, says shares ‘significantly cheap’